The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

Wed, 27th Dec 2023 07:52

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

After the early close in London on Friday, data from the US showed inflation eased a bit more in November.

The Bureau of Economic Analysis said the core personal consumption expenditures price index rose annually by 3.2% in November, slowing from 3.4% in October, which was first reported at 3.5%. The latest figure was just below the FXStreet-cited market consensus of 3.3%. The core reading, the Federal Reserve's preferred inflation gauge, does not include food or energy.

"The market optimism is overstretched. The Fed's rate cut expectations are unfunded in that, yes, the Fed will probably cut rates but not at the speed that's been currently priced in. The oversold market conditions do hint that a downside correction would be healthy. Once the Santa high fades, the hangover will hit," predicted Ipek Ozkardeskaya, senior analyst at Swissquote Bank.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up 44.0 points, 0.6%, at 7,741.51

----------

Hang Seng: up 2.0% at 16,663.05

Nikkei 225: closed up 1.1% at 33,681.24

S&P/ASX 200: closed up 0.8% at 7,561.20

----------

DJIA: closed up 0.4% at 37,545.33

S&P 500: closed up 0.4% at 4,774.75

Nasdaq Composite: closed up 0.5% at 15,074.57

----------

EUR: up at USD1.1043 (USD1.1019)

GBP: up at USD1.2730 (USD1.2719)

USD: up at JPY142.67(JPY142.14)

Gold: up at USD2,065.64 per ounce (USD2,055.55)

(Brent): up at USD81.14 a barrel (USD80.02)

(changes since previous London equities close on Friday)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

08:55 EST US Johnson Redbook retail sales index

10:00 EST US Richmond Fed business activity survey

16:30 EST US API weekly statistical bulletin

----------

UK Conservatives have been dropping hints they could make attention-grabbing pledges on housing and taxes as Prime Minister Rishi Sunak struggles to turn around his party's major deficit in the polls. Housing Secretary Michael Gove suggested to the Times that the Conservatives will promise to cut the up-front cost of a home for first-time buyers in a pre-election giveaway. And the prime minister has ordered a "gear change" to reduce the historically high tax burden, possibly axing inheritance tax and reducing income tax, according to the Telegraph. The Times said that UK government ministers are considering government support for longer fixed-term mortgages to reduce the size of deposits for first-time buyers. A resurrected help-to-buy scheme was also said to be on the table for the spring budget or the Conservative election manifesto. Meanwhile, the Telegraph said senior figures in No 10 were considering a handful of major tax cuts as Sunak comes under continued pressure from Tory MPs.

----------

COMPANIES - FTSE 100

----------

AstraZeneca said it has agreed to buy Nasdaq-listed Gracell Biotechnologies and will pay about USD1.2 billion for the clinical-stage company. The Cambridge, England-based pharmaceutical company said it expects the acquisition to close in the first quarter of 2024. Gracell is a Suzhou, China-based biopharmaceutical firm developing cell therapies for cancer and autoimmune diseases. AstraZeneca will pay USD2.00 per share, or USD10.00 per American Depositary Receipt, for Gracell at closing, plus USD0.30 per share "upon achievement of a specified regulatory milestone". The upfront cash portion represents a transaction value of around USD1.0 billion, with the total value being about USD1.2 billion if the milestone is achieved. Gracell ADSs closed up 60% at USD9.92 in New York on Tuesday.

----------

COMPANIES - FTSE 250

----------

HgCapital Trust said its manager Hg agreed a partial sale of Iris Software Group, which provides software and services in accountancy, payroll, human resources and eduction to a Los Angeles-based private equity firm. The terms of Hg's transaction were not disclosed, but HGT said the deal valued its investment in Iris at around GBP99.8 million. "HGT will receive a net distribution of approximately GBP42.1 million from Iris, having re-invested a portion of its proceeds in the business alongside other institutional clients of Hg investing through Hg Saturn. As part of the transaction, Hg's Saturn 1 fund will fully exit its remaining position in Iris. HGT's exposure to Iris will be GBP57.7 million at closing representing approximately 2.5% of [net asset value]," HGT explained.

----------

OTHER COMPANIES

----------

Stockbroker and wealth manager WH Ireland reported a weaker set of results for the six months that ended September 30. Pretax loss widened to GBP3.9 million from GBP384,000 a year before, as revenue dropped to GBP10.7 million from GBP14.3 million and WH Ireland took GBP1.7 million in non-recurring costs. Assets under management for its Wealth Management division shrunk to GBP1.8 billion from GBP2.1 million a year before, while the number of corporate clients in its Capital Markets unit slipped to 86 from 90 a year prior. "WH Ireland's interim results reflect both the well documented challenging market backdrop, as well as the impact of the non-recurring costs incurred in streamlining the business after the refinancing in the summer," said CEO Phillip Wale. Market conditions have shown "some tentative signs of improvement" since November, he added, which has enabled WH Ireland to undertake some its largest fundraising in many months across public and private markets. The business delivered underlying monthly profitability in November, he noted.

----------

Canadian Overseas Petroleum said its chief executive officer, John Cowan, has resigned. Cowan will remain on the board for the time being while a replacement is found, COPL said. No reason was provided for his resignation. The oil and gas explorer had a challenging week in the run-up to Christmas, with its shares plunging 70%. It had reported last Monday that its non-binding Cole Creek joint venture letter of intent with "an established energy company" has been terminated, and it planned "no further discussions at this stage". It followed up on Wednesday to say its indirect affiliate COPL America's senior lender was unwilling to amend or waive the terms of its senior credit facility. COPL said it expects to require additional financing in January, with no assurance that funds will be secured. "Should the company be unsuccessful in raising the required capital, it would have to seek some form of creditor protection," it had warned.

----------

By Elizabeth Winter, Alliance News deputy news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.